据悉，作为国内AI医疗行业领头羊，医渡科技持续投入人工智能技术，特别是自研医疗垂类大语言模型的研发和商业化，并推动AI落地具体场景。光大证券指出，考虑到AI医疗智能大脑YiduCore赋能全场景解决方案落地，经调整EBITDA持续盈利，维持“买入”评级。Yidu Technology (02158) rose nearly 7% in the morning session, and as of the time of writing, it has increased by 6.06%, priced at 5.95 Hong Kong dollars, with a transaction volume of 0.141 billion Hong Kong dollars.
According to the Zhito Finance APP, Yidu Technology (02158) rose nearly 7% in the morning session, and as of the time of writing, it has increased by 6.06%, priced at 5.95 Hong Kong dollars, with a transaction volume of 0.141 billion Hong Kong dollars.
In terms of news, AI-assisted diagnosis has been included for the first time in the national medical insurance bureau project guideline. On November 23, the national medical insurance bureau stated at a related press conference that 17 batches of project guidelines have been prepared and published to standardize and guide local pricing projects. To support relatively mature AI-assisted technologies in entering clinical applications while preventing additional burdens on patients, the national medical insurance bureau analyzed potential application scenarios for AI and established 'AI-assisted' extension items in radiological examinations, ultrasound examinations, and rehabilitation projects.
It is reported that as a leader in the domestic AI Medical Industry, Yidu Technology continuously invests in AI technology, especially in the research and commercialization of self-developed medical vertical large language models, and promotes the implementation of AI in specific scenarios. Everbright Securities pointed out that considering the AI medical intelligent brain YiduCore empowering full-scenario solutions, adjusted EBITDA continues to remain profitable, maintaining a 'Buy' rating.
